Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
Crossref DOI link: https://doi.org/10.1007/s00296-016-3423-5
Published Online: 2016-01-16
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dalén, Johan
Svedbom, Axel
Black, Christopher M.
Lyu, Ramon
Ding, Qian
Sajjan, Shiva
Sazonov, Vasilisa
Kachroo, Sumesh
Funding for this research was provided by:
Merck (US)
Text and Data Mining valid from 2016-01-16